ArticleOncology reports2019
MicroRNA‑203a‑3p is a candidate tumor suppressor that targets thrombospondin 2 in colorectal carcinoma.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Divergent jejunal cis- and trans-eQTLs and their microbiome associations following a diet lacking mineral phosphorus supplements in laying hens.BMC genomics · 2026Article
- Analysis of the Circulating miRNome Expression Profile in Saliva Samples After Neoadjuvant Chemoradiotherapy in a Rectal Cancer Study Population Using Next-Generation Sequencing.International journal of molecular sciences · 2025Article
- The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications.Non-coding RNA research · 2025Review
- LINC00704 boosts the immunologic escape of colorectal cancer cells by upregulating TLR4 by binding with miR- 203a- 3p.European journal of medical research · 2025Article
- CD44 knockdown alters miRNA expression and their target genes in colon cancer.Frontiers in immunology · 2025Article
- Role of hsa_Circ_0001821 in Colorectal Cancer Pathogenesis and Response to 5-Fluorouracil through miR-203a-3p/FGF-2 AxisIranian biomedical journal · 2025Article
- Thrombospondin 2, matrix Gla protein and digital analysis identified distinct fibroblast populations in fibrostenosing Crohn's disease.Scientific reports · 2024Article
- MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions.International journal of molecular sciences · 2023Article
- Circ_0079530 stimulates THBS2 to promote the malignant progression of non-small cell lung cancer by sponging miR-584-5p.Histology and histopathology · 2023Article
- Identification of BGN and THBS2 as metastasis-specific biomarkers and poor survival key regulators in human colon cancer by integrated analysis.Clinical and translational medicine · 2022Article
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- Circ_0007580 knockdown strengthens the radiosensitivity of non-small cell lung cancer via the miR-598-dependent regulation of THBS2.Thoracic cancer · 2022Article
- Identification of CXCL10 and CXCL11 as the candidate genes involving the development of colitis-associated colorectal cancer.Frontiers in genetics · 2022Article
- The Regulation of Collagen Processing by miRNAs in Disease and Possible Implications for Bone Turnover.International journal of molecular sciences · 2021Review
- Extracellular Matrix Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Review
- MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Predominant Distribution of the RNAi Machinery at Apical Adherens Junctions in Colonic Epithelia Is Disrupted in Cancer.International journal of molecular sciences · 2020Article
- miR-654-3p predicts the prognosis of hepatocellular carcinoma and inhibits the proliferation, migration, and invasion of cancer cells.Cancer biomarkers : section A of Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the role of miR‑203a‑3p in colorectal cancer (CRC) and identify the target gene of microRNA (miR)‑203a‑3p. A total of 59 sets of cancer tissues and corresponding adjacent non‑tumor tissues were collected from CRC patients (aged 31‑78 years) between October 2016 and May 2017. Total RNA extraction and reverse transcription‑quantitative polymerase chain reaction analysis, transfection assay, and Transwell and apoptosis assays, western blot analysis, a luciferase reporter assay and immunohistochemistry were performed. miR‑203a‑3p was found to be significantly downregulated in CRC tissues compared with adjacent normal tissues. The overexpression of miR‑203a‑3p was shown to inhibit the invasion and migration of human CRC SW480 and HT29 cells, and increase their apoptosis rates. Furthermore, miR‑203a‑3p downregulated the expression of thrombospondin 2 (THBS2) in SW480 and HT29 cells. It was also experimentally demonstrated that miR‑203a‑3p binds to the 3'‑untranslated region of THBS2, downregulating THBS2 expression and thereby inhibiting CRC progression and metastasis. The expression of miR‑203a‑3p, which serves a tumor‑suppressive role, in CRC tissues was significantly downregulated. As miR‑203a‑3p was determined to target THBS2 to inhibit CRC progression and metastasis; thus, miR‑203a‑3p may be considered as a potential novel approach to treating CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.